Organogenesis Appoints Jon Giacomin to Board of Directors
May 10 2021 - 7:30AM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical & Sports Medicine markets, today announced the
appointment of Jon Giacomin to the Company’s Board of Directors,
effective May 7, 2021. The Company also announced that Wayne Mackie
resigned as a member of the Company’s Board of Directors effective
May 7, 2021. Mr. Mackie’s resignation was not due to any
disagreement with the Company on any matter relating to its
operations, policies or practices.
“Jon is a proven leader who brings significant
expertise from a nearly 30-year career in the healthcare sector,”
said Gary S. Gillheeney, Sr., President and Chief Executive Officer
of Organogenesis. “We believe his demonstrated capabilities in
leading large, diversified healthcare businesses make him an ideal
addition to our Board of Directors, and we look forward to
leveraging his guidance and insight during our next phase of growth
and development.”
Mr. Gillheeney continued: “On behalf of the
Board of Directors, I would like to thank Wayne for his important
contributions to the Organogenesis Board.”
Mr. Giacomin currently serves as the Chief
Executive Officer of U.S. Anesthesia Partners, Inc. (“USAP”), a
privately-owned, single-specialty anesthesia practice that serves
over 2.3 million patients across the nation annually. Prior to
joining USAP, Mr. Giacomin held various leadership positions at
Cardinal Health, Inc. (NYSE: CAH) from 2001 to 2019, a leading
distributor of pharmaceuticals, global manufacturer and distributor
of medical and laboratory products and provider of performance and
data solutions for health care facilities. Mr. Giacomin most
recently served as Chief Executive Officer of Cardinal Health’s
Medical Segment, a business which generated over $15 billion in
revenue during the most recently completed fiscal year. During his
career at Cardinal Health, he also served as Chief Executive
Officer of its Pharmaceutical Segment from 2014 to 2018, which
generated over $130 billion in revenue during the most recently
completed fiscal year.
Mr. Giacomin began his career as a Nuclear
Engineer and Surface Warfare Officer in the U.S. Navy and
subsequently held positions at Sotera Health Company (Nasdaq: SHC)
and Griffith Micro Science International Inc. before joining
Cardinal Health. He holds a B.S. in Mechanical Engineering from the
University of Notre Dame, and an MBA in Finance from the University
of Chicago’s Booth School of Business.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements regarding Organogenesis
Holdings’ expected growth opportunities and strategy to deliver
strong growth and improving profitability, that involve a number of
risks and uncertainties. Statements that are not historical facts
are based on Organogenesis Holdings’ current expectations, beliefs
and assumptions. There can be no assurance that Organogenesis
Holdings will grow or improve its profitability. Important factors
that could cause actual outcomes to differ materially from those
indicated by these forward-looking statements include, but are not
limited to: (1) the Company has incurred significant losses
since inception and may incur losses in the future; (2) the
Company faces significant and continuing competition, which could
adversely affect its business, results of operations and financial
condition; (3) rapid technological change could cause the
Company’s products to become obsolete and if the Company does not
enhance its product offerings through its research and development
efforts, it may be unable to effectively compete; (4) to be
commercially successful, the Company must convince physicians that
its products are safe and effective alternatives to existing
treatments and that its products should be used in their
procedures; (5) the Company’s ability to raise funds to expand
its business; (6) the impact of any changes to the
reimbursement levels for the Company’s products and the impact to
the Company of the loss of preferred “pass through” status for
PuraPly AM and PuraPly on October 1, 2020; (7) changes in
applicable laws or regulations; (8) the possibility that the
Company may be adversely affected by other economic, business,
and/or competitive factors; (9) the Company’s ability to
complete the relaunch of Affinity and to maintain production in
sufficient quantities to meet demand;
(10) the COVID-19 pandemic and its impact, if any,
on the Company’s fiscal condition and results of operations; and
(11) other risks and uncertainties described in the Company’s
filings with the Securities and Exchange Commission, including Item
1A (Risk Factors) of the Company’s Form 10-K for the year
ended December 31, 2019 and its subsequently filed periodic
reports. Organogenesis Holdings cautions investors not to
place undue reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this
release, and Organogenesis Holdings undertakes no obligations to
update or revise these statements, except as may be required by
law.
About Organogenesis Holdings
Inc.
Organogenesis Holdings Inc. is a leading
regenerative medicine company offering a portfolio of bioactive and
acellular biomaterials products in advanced wound care and surgical
biologics, including orthopedics and spine. Organogenesis’s
comprehensive portfolio is designed to treat a variety of patients
with repair and regenerative needs.
Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
Lori Freedman
lfreedman@organo.com
Cardinal Health (NYSE:CAH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cardinal Health (NYSE:CAH)
Historical Stock Chart
From Sep 2023 to Sep 2024